Trials open to recruitment Trials closed to recruitment

IBCSG 65-21 / BIG 19-02 DECRESCENDO

De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade.

    Trial Coordinator
    Dorene Polizzi

    Monitoring
    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email:     This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Targeted Accrual
    Estimated number of subjects to screen: 1330 (assuming a 20% rate of screen failure)
    Estimated number of subjects to enrol: 1065

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    android icon 48x48Donating & Supporting

    Member Login